Heard a crushing sound lately? It might have come the market's beat-down this week of three particularly unfortunate health-care stocks.
One of the week's biggest losers plunged on news of the U.S. Food and Drug Administration's denial of Breakthrough Therapy Designation for the company's lead drug. Another stock stumbled after investors learned that the company didn't disclose potential safety concerns from a clinical trial that ended early after meeting its primary endpoint. The third poor performer saw shares drop after announcing the departure of a top executive.
Which stocks got crushed the most this week? Find out by watching the following slideshow.
Will this stock be the one that helps you crush the market?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.